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Abstract
Objective: First, to investigate and compare associations between alcohol consumption and variants in alcohol
dehydrogenase (ADH) genes with incidence of cardiovascular diseases (CVD) in a large German cohort. Second, to
quantitatively summarize available evidence of prospective studies on polymorphisms in ADH1B and ADH1C and CVD-risk.
Methods: We conducted a case-cohort study nested within the European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam cohort including a randomly drawn subcohort (n=2175) and incident cases of myocardial
infarction (MI; n=230) or stroke (n=208). Mean follow-up time was 8.262.2 years. The association between alcohol
consumption, ADH1B or ADH1C genotypes, and CVD-risk was assessed using Cox proportional hazards regression.
Additionally, we report results on associations of variants in ADH1B and ADH1C with ischemic heart disease and stroke in the
context of a meta-analysis of previously published prospective studies published up to November 2011.
Results: Compared to individuals who drank .0 to 6 g alcohol/d, we observed a reduced risk of MI among females
consuming .12 g alcohol/d (HR=0.31; 95% CI: 0.10–0.97) and among males consuming .24 to 60 g/d (HR=0.57; 95% CI:
0.33–0.98) or .60 g alcohol/d (HR=0.30; 95% CI: 0.12–0.78). Stroke risk was not significantly related to alcohol consumption
.6 g/d, but we observed an increased risk of stroke in men reporting no alcohol consumption. Individuals with the slow-
coding ADH1B*1/1 genotype reported higher median alcohol consumption. Yet, polymorphisms in ADH1B or ADH1C were
not significantly associated with risk of CVD in our data and after pooling results of eligible prospective studies [ADH1B*1/1:
RR=1.35 (95% CI: 0.98–1.88; p for heterogeneity: 0.364); ADH1C*2/2: RR=1.07 (95% CI: 0.90–1.27; p for heterogeneity:
0.098)].
Conclusion: The well described association between alcohol consumption and CVD-risk is not reflected by ADH
polymorphisms, which modify the rate of ethanol oxidation.
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Introduction
Considerable epidemiologic evidence links moderate alcohol
consumption to a reduced risk of coronary heart disease (CHD)
and stroke [1]. Because alcohol consumption is related to many
potentially confounding factors, the causal effect of alcohol
consumption on CVD risk is difficult to assess in observational
studies. Long-term randomized controlled trials investigating the
effects of regular alcohol consumption on hard cardiovascular
endpoints are unlikely to be ever carried out. However, short- to
medium-term intervention studies have demonstrated a favorable
effect of ethanol on lipids, haemostasis, and insulin sensitivity [2].
As biologically plausible mediators these mechanisms may be
viewed as an indirect support for a protective effect of moderate
alcohol use on cardiovascular events.
In addition, genetic variants associated with average alcohol
consumption and/or circulating ethanol levels may act as
unconfounded and precisely measured markers of the exposure
and thereby contributing to strengthen causal inference [3]. In this
respect, genes coding for alcohol dehydrogenases (ADH) deserve
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In humans, five ADH classes exist and functional polymorphisms
in the genes ADH1B and ADH1C produce isoenzymes with
different maximal activities (Vmax) and affinities for ethanol [4]. At
the ADH1C locus, two single nucleotide polymorphisms (SNPs) in
very strong linkage disequilibrium have been described [5]. The
respective alleles ADH1C*1 and ADH1C*2 code for two ADH
subunits (g1 and g2) which differ at amino acid positions 271 and
349. Compared to the homodimeric g2 isoenzyme, g1g1 has a 2.5-
fold higher Vmax of ethanol oxidation [6]. An even 40-fold
difference in Vmax has been observed between b1b1 and the fast
metabolizing b2b2 isoenzyme, resulting from variation at
rs1229984 (ADH1B Arg48His) [4].
A few prospective studies have investigated the association
between alcohol consumption and risk of cardiovascular diseases
(CVD) in combination with variations in genes coding for ADH1C
or ADH1B [7,8,9,10,11,12,13]. In line with the hypothesis that
ethanol is largely responsible for the inverse association between
alcohol consumption and coronary events, individuals with the
slow ADH1C*2/2 genotype had a lower risk of myocardial
infarction (MI) in a study among male physicians [9]. However,
later studies on this subject were inconsistent [7,8,10,11,12].
Comparable data on polymorphisms in ADH1B is rare because of
the low frequency of the ADH1B
*2 allele in caucasians [14]. Risk
of MI did not change across ADH1B genotypes in a Danish
population [10], whereas the ADH1B*1 allele coding for the slow
isoenzyme was associated with a higher prevalence of cerebral
infarction in Japanese men but not in women [15].
In this study we examined and compared the associations of
alcohol consumption and SNPs in ADH1C and ADH1B with
incident cardiovascular events in a prospective cohort. To
summarize the available evidence on polymorphisms in the above
genes with ischemic heart disease and stroke, we also carried out a
meta-analysis of prospective population-based studies.
Methods
Ethics statement
Study procedures were approved by the Ethics Committee of
the medical association of the State of Brandenburg (Germany)
and all participants gave their written informed consent.
Study design and study population
The European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam study is part of the large-scale EPIC
cohort and includes 10,904 male and 16,644 female participants
recruited from the general population of Potsdam and surrounding
areas. The preferred age range for recruitment was 35–65 years.
Baseline examination was conducted from 1994 through 1998 and
included blood sampling, measurements of blood pressure and
anthropometric parameters, self-administered questionnaires on
diet and lifestyle, and personal computer-assisted interviews [16].
Data on ADH1C and ADH1B genotypes was not available for
the whole cohort, but only for a case-cohort study nested within
the EPIC-Potsdam cohort, which has been described elsewhere
[17]. With this type of study design, the results are expected to be
generalizable to the source population without the need to
measure the polymorphisms in the entire cohort [18]. For reasons
of consistency, all analyses were performed in this case-cohort
study.
Selection of cases. After excluding EPIC-Potsdam
participants with a history of MI or stroke at baseline, we
identified 269 individuals with incident MI and 246 individuals
with incident stroke occurring between baseline examination and
30
th November 2006 (mean follow-up time 8.262.2 years). In 6
individuals with more than one cardiovascular event, only the first
event was considered. For the present analyses, we excluded 41
cases of MI and 34 stroke cases because blood specimens were not
available or because of missing values in relevant covariates,
dietary or genetic data.
Selection of the subcohort. For the subcohort, we randomly
selected 2500 individuals from the EPIC-Potsdam cohort.
Consistent with the applied case-cohort design, the subcohort
included 60 subjects who experienced MI or stroke during the
study period. In the subcohort, we excluded participants with a
history of MI or stroke at baseline, with missing follow-up data,
unavailable blood samples, or missing information on relevant
covariates, alcohol consumption data or the SNPs.
Thus, our analyses are based on a case-cohort sample of 2558
individuals (230 MI cases, 208 stroke cases, and 2175 who
remained free of MI or stroke during follow-up).
Ascertainment of incident MI and stroke
Potential cases of incident MI or stroke were identified by death
certificate or by self-report in one of the four biennial follow-up
questionnaires [19]. To reduce the number of false-negative
reports, the questionnaire also contained items on stroke
symptoms, as described earlier [20]. The diagnosis was verified
by review of medical records from the hospital, by contacting the
patients’ attending physician, or by review of death certificates
according to WHO criteria. Cases were subsequently classified as
incident MI (ICD-10 I21), ischemic stroke (ICD-10 I63.0–I63.9),
intracerebral (ICD-10 I61.0–I61.9) or subarachnoidal hemorrhage
(ICD-10 I60.0–I60.9), or undetermined stroke (ICD-10 I64.0–
I64.9) [21].
Assessment of alcohol consumption
Dietary habits including alcohol consumption were assessed at
baseline by use of a validated, self-administered food frequency
questionnaire [22]. Baseline alcohol consumption was calculated
based on the reported number of glasses of alcoholic beverages
consumed during the 12 months prior to recruitment. Assuming
one standard drink to be equivalent to 12 g of pure alcohol [23],
baseline alcohol consumption was modeled using the following
categories: non-drinker, .0 to 6 g/d (.0 to 0.5 drink/d), .6t o
12 g/d (.0.5 to 1 drink/d), .12 to 24 g/d (.1 to 2 drinks/d),
.24 to 60 g/d (.2 to 5 drinks/d), .60 g/d (.5 drinks/d).
Because the average alcohol consumption was lower among the
women than among the men, we combined the two highest
consumption categories in women. Information on past consump-
tion of alcoholic beverages at 20, 30, and 40 years of age was
obtained by a lifestyle questionnaire. This information was
combined to define three groups: never use of alcohol in the past,
heavy alcohol consumption at one or more time points in the past,
never heavy alcohol consumption at any time in the past. Heavy
alcohol consumption was defined as 60 g/d in men and 30 g/d in
women, thus reflecting 2.5 times the upper recommended limit of
two standard drinks a day for men and one standard drink a day
for women [24].
Assessment of covariates
Smoking habits, physical activity, educational attainment, and
medical history were assessed during a standardized interview. We
divided the study population according to their smoking status into
never smokers, former smokers .5 years, former smokers #5
years, smokers ,20 units/day, and smokers $20 units/day; with
one unit being equivalent to one cigarette/cigar/pipe. Physical
activity was expressed as the mean duration of leisure time
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variable was dichotomized using a cut point of $2 h/week.
Educational attainment was expressed as vocational school or less,
technical school, and university degree.
Baseline measurements of anthropometric parameters and
blood pressure were obtained by trained personnel [25]. BMI
was calculated as the ratio of body weight (kg) to height squared
(m
2). Systolic and diastolic blood pressure (BP) was measured after
a resting period of 15–30 minutes. Prevalent hypertension was
defined as systolic BP$140 mmHg, diastolic BP$90 mmHg, self-
reported hypertension diagnosis, or use of antihypertensive
medication. The prevalence of diabetes mellitus at baseline was
evaluated by a study physician using information on self-reported
medical diagnosis, medication records, and dieting behaviors. In
ambiguous cases, the diagnosis was confirmed by personal
communication with the participant and/or treating physician.
Blood collection and laboratory analyses
During baseline examination, peripheral venous citrate blood
samples were taken and subsequently centrifuged at 10006g for
10 min at 4uC. Plasma was aliquoted and stored in liquid nitrogen
at 2196uC. Plasma levels of total cholesterol were measured with
the automatic ADVIA 1650 analyzer (Siemens Medical Solutions,
Erlangen, Germany). Genomic DNA was extracted from periph-
eral blood leukocytes using the Qiagen QIAamp 96 Blood Kit.
Following whole genome amplification (GenomiPhi DNA Ampli-
fication Kit, Amnersham Biosciences), genotyping was performed
with the TaqMan SNP Genotyping Assay using the ABI PRISM
7900HT Sequence Detection System according to the manufac-
turer’s protocol (Applied Biosystems, Foster City, CA, USA). The
genotyping success rates in SNPs rs1229984 and rs698 were
98.8% and 99.4%, respectively.
Statistical analysis
Statistical analysis was performed using SAS software package,
release 9.2 (SAS Institute, Cary, NC). All tests were performed
two-sided with p,0.05 considered as statistically significant.
For subjects of the subcohort we calculated means 6 standard
deviation (SD) or frequencies of selected baseline characteristics
across categories of alcohol consumption. As drinking habits and
participant characteristics are likely to differ between men and
women, gender-specific values are presented. To investigate the
association of alcohol consumption with risk of CVD, MI, and
stroke, we conducted Cox proportional hazards regression
adapted for the case-cohort design using the weighting method
described by Prentice [18]. To examine the association of alcohol
consumption with CVD risk, gender-specific multivariable-adjust-
ed hazard ratios (HR) were derived using subjects with an alcohol
consumption of .0 to 6 g/d as the reference group. Because of
the dependence among observations introduced by the case-cohort
design, we used robust standard errors obtained from the robust
sandwich covariance estimates for calculating 95% confidence
intervals (CI). For the counting process style of input, the subjects’
age at recruitment was used as the entry time and age at censoring
or at diagnosis of MI or stroke as the exit time. All models were
stratified according to age at recruitment in one year categories
and adjusted for BMI (kg/m
2), waist circumference (cm), smoking
status (never smokers, former smokers .5 years, former smokers
#5 years, smokers ,20 units/day, and smokers $20 units/day),
educational attainment (vocational school or less, technical school,
university), physical activity $2 h/week, non-alcohol energy
intake (kJ/d), prevalent hypertension, prevalent diabetes mellitus,
and plasma total cholesterol level. In additional models we also
adjusted for reported past alcohol consumption and polymor-
phisms in ADH1B and ADH1C.
The x
2 test was used to determine whether the distributions of
ADH1B and ADH1C genotypes were in Hardy-Weinberg equilib-
rium among subjects of the subcohort. As expected from their
random allocation at meiosis, the distribution of the investigated
alleles was comparable between men and women. Therefore, to
increase statistical power, both genders were combined for all
analyses involving SNP data. We also examined the associations
between ADH genotypes with risk of MI/stroke in models
stratified by age and adjusting for the above mentioned covariates
plus gender. For that purpose, subjects with a genotype coding for
a faster isoenzyme – ADH1C*1/1 and ADH1B*1/2 or 2/2 – were
used as the respective reference group. The impact of alcohol
consumption on these associations was analyzed in models
additionally adjusted for the categories of baseline alcohol
consumption defined above. To test for interaction, we used a
likelihood ratio test to compare a model including alcohol
consumption (0 g/d, .0 to 12 g/d (women)/.0 to 24 g/d
(men), .12 g/d (women)/.24 g/d (men)) and the ADH1C
genotypes with a model additionally including the interaction
terms. Because of low number of cases with the fast-metabolizing
ADH1B*1/2 or 2/2 genotypes, we were unable to further stratify
this group and therefore, no p-values for interactions are reported
for ADH1B.
The power for detecting an association between ADH
polymorphisms and MI or stroke was calculated based on an
algorithm developed for case-cohort studies [26] and assuming an
incidence rate of 0.01, a sampling rate of 0.08 for the random
subcohort, and an allele frequency of 58% for the ADH1C*1 allele
and 2% for the ADH1B
.2 allele [27]. With an alpha of 0.05, we
had 84% power to detect an HR for either MI or stroke of 0.70 for
the comparison of ADH1C*2/2 (slow) versus ADH1C*1/1 (fast),
which is an effect size similar to what was found by Hines et al. [9].
For the comparison of individuals with the ADH1B
*1/1 genotype
(slow) with ADH1B*1/2 or ADH1B*2/2 (fast), power was only
43% to detect an HR of 0.70. That’s why we also conducted a
meta-analysis to pool our results with results obtained from
comparable studies.
Meta-analysis
For a meta-analysis, we aimed to identify prospective studies
investigating SNPs in the ADH1B or ADH1C gene in relation to
incidence of ischemic heart disease or stroke. For that purpose we
searched Medline, EMBASE, and Web of Science for studies
published by November 24, 2011. No language restriction was
applied. The following search strategy was applied: 1) Coronary
OR Myocardial OR Heart OR Cerebral OR Cerebrovascular
OR Brain; 2) Syndrome OR Disease* OR Infarction* OR
Attack*; 3) (#1 AND #2); 4) Alcohol dehydrogenase*; 5)
Prospective OR Cohort OR Longitudinal OR Incidence; 6) #3
AND #4 AND #5. The search in Medline and EMBASE was
limited to human studies. For the Medline search, we additionally
included the terms ‘‘OR ’’Myocardial Ischemia‘‘ [MeSH] OR
’’Stroke‘‘ [MeSH]’’ in #3, ‘‘OR ’’Alcohol Dehydrogenase‘‘
[MeSH]’’ in #4, ‘‘OR ’’Cohort studies‘‘ [MeSH]’’ in #5. In
EMBASE, we replaced these MeSH terms by the respective index
terms ‘Ischemic Heart Disease’, ‘Stroke’, ‘Alcohol Dehydroge-
nase’, and ‘Cohort Studies’.
Our search identified 44 references which were reviewed by two
independent assessors (DD and RdG). A total of 36 references
were excluded for the following reasons: no original data (n=15),
no relevant outcome (n=16), no relevant exposure (n=3), no
relevant study design (n=2). Thus, eight studies met our inclusion
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ischemic heart disease included studies on CHD [7,8,12], MI
[9,10], and acute coronary events [11]. In total, two of the
identified studies analyzed SNP rs1229984 in the ADH1B gene
[10,11] and seven analyzed either SNP rs698 [8,9,10,12,13] or
rs1693482 [7,11] in the ADH1C gene. Because the latter are in
very high linkage disequilibrium [5], we combined this data.
Scanning the references of the retrieved reports did not lead to as
yet unknown eligible studies.
Two authors (DD and RdG) independently extracted and
tabulated information on study design, study population, sample
size, the number of cases, outcome, the investigated SNP as well as
point estimates and 95% CI from the original reports. Discrep-
ancies were resolved via review of the original articles. For three
studies that did not provide information on risk estimates and 95%
CI, we attempted to obtain it by correspondence with the authors
[7,11,12]:
N One reply enabled additional unpublished data of the Second
Northwick Park Heart to be incorporated in the meta-analysis
(PJ Talmud, personal communication) [12].
N One study was excluded from the meta-analysis because we
were unable to obtain the requested results [11].
N Because we were unable to obtain data for the study of
Ebrahim et al. [7], we used the reported crude incidence rates
of CHD across ADH1C genotypes to calculate Relative Risks
(RR) and 95% CI as described by Rothman et al. [28].
The meta-analysis was performed using the R software (version
2.12.1) and the package meta [29]. Pooled estimates of RR and
95% CI were obtained by means of a random effects approach
with study-specific exposure-disease effects weighted according to
the inverse of their variances plus the common between-studies
variance [30]. Heterogeneity was estimated using the I
2 statistic
and tested using the Q statistic. Publication bias was evaluated by
visual inspection of the funnel plot and the tests of Begg and
Mazumdar [31] and of Egger et al. [32]. These tests were
conducted for data on ADH1C only, because only one report was
eligible for the meta-analysis on ADH1B in addition to our own
data.
Results
The present analyses are based on 2558 subjects including 438
major CVD events (MI: n=230; IS: n=169; HS: n=35;
undetermined stroke: n=4). Among subcohort participants about
50% of women consumed .0 to 6 g/d (Table 1) whereas most
men (32%) reported an alcohol consumption of .24 to 60 g/d
(Table 2). In both genders, never smoking was most prevalent in
those reporting low alcohol consumption (.0 to 6 g/d) and the
highest proportion of prevalent type 2 diabetes was observed
among individuals with zero alcohol consumption at baseline.
Compared to individuals consuming .0 to 6 g alcohol/d there
was a significantly lower risk of MI among females consuming
.12 to 24 g alcohol/d (HR=0.31; 95% CI 0.10 to 0.97; Table 3)
and among males consuming .24 to 60 g/d (HR=0.57; 95% CI
0.33 to 0.98) or .60 g/d (HR=0.30; 95% CI 0.12 to 0.78;
Table 4). Further adjustment for past drinking behaviors or
genotypes of ADH1B and ADH1C did not materially change risk
estimates associated with moderate to high alcohol consumption.
Because only one man and 14 women reported lifelong abstinence
from alcohol, we had insufficient power to derive risk estimates for
this group. Excluding them from the analyses resulted in a
HR=1.51 (95% CI: 0.62–3.68) for men and a HR=1.52 (95%
CI: 0.41–5.61) for women consuming no alcoholic beverages at
baseline but with an alcohol consumption.0 g/d at any point in
their past.




.0t o6g / d
n=708 (58.1%)
.6t o1 2g / d
n=324 (23.8%)




Age, y, mean 6 SD 52.6611.5 49.669.4 47.969.0 47.868.8 47.368.6
BMI, kg/m
2, mean 6 SD 25.564.8 26.164.9 25.564.6 25.264.1 2564.0
Waist circumference, cm, mean 6 SD 80.5611.5 81.5612.3 80.2611.3 79.8610.8 79.1610.5
ADH1C genotype, %
ADH1C*1/1 (fast) 28.6 34.6 32.7 39.1 29.7
ADH1C*1/2 (intermediate) 54.3 48.7 50.0 47.4 51.5
ADH1C*2/2 (slow) 17.1 16.7 17.3 13.5 18.8
ADH1B*1/1 (slow) 88.6 90.7 92 92.2 92.1
Smoking status, %
Never smokers 57.1 63.6 56.5 48.4 39.6
Past smokers .5 years 17.1 13.6 18.8 24.5 26.7
Past smokers #5 years 5.7 6.6 8.6 5.2 8.9
Current smokers ,20 units 14.3 13.6 13.6 16.1 19.8
Current smokers $20 units 5.7 2.7 2.5 5.7 5.0
University degree, % 37.1 23.2 36.1 38.5 31.7
Physical activity .=2 h/week, % 31.4 21.9 24.4 26.6 29.7
Hypertension, % 57.1 41.9 40.1 37.0 42.6
Diabetes mellitus, % 5.7 3.5 0.6 3.6 5.0
Total cholesterol, mg/dl, mean 6 SD 182.5643.0 174.1636.3 166.2640.7 171.1638.0 171.4635.9
doi:10.1371/journal.pone.0032176.t001
Alcohol Consumption, ADH Polymorphisms and CVD
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32176Risk of stroke was not significantly related to alcohol consump-
tion above 6 g/d (Tables 3 and 4). However, abstinence from
alcohol at baseline was associated with a significantly increased risk
of stroke in men (HR=3.57; 95% CI: 1.13–11.32). We had
insufficient case numbers to perform a sub-analysis for hemorrhagic
stroke. Yet, when restricting the outcome to ischemic stroke the HR
for .6 to12 g/d, .12 to 24 g/d, .24 to 60 g/d, and .60 g/d
were 1.01 (95% CI: 0.47–2.17), 1.07 (95% CI: 0.51–2.25), 1.68
(95% CI: 0.85–3.32), 1.01 (95% CI: 0.41–2.46) in men compared to
the reference group (data not shown in a table). In women, HR of
ischemic stroke associated with .6 to12 g/d, .12 to 24 g/d,
.24 g/d were 1.28 (95% CI: 0.71–2.31), 1.11 (95% CI: 0.53–2.30),
and 0.52 (95% CI: 0.14–1.87), respectively.
Among the individuals of the subcohort, frequencies of
ADH1B*1/1 and ADH1C*2/2 coding for the respective less active
isoenzymes were 91.6% and 17.4%. The distributions of the
investigated ADH genotypes were in Hardy-Weinberg equilibrium
(ADH1B: p=0.991; ADH1C: p=0.993). We observed no significant
association between ADH1C genotypes and alcohol consumption
(Tables 1 and 2, Figure 1). In comparison, the frequency of the slow
metabolizing ADH1B variant (ADH1B*1/1) was lowest in men
consuming .0 to 6 g/d and gradually increased with increasing
alcohol consumption(Table 1).Inline with thisobservation,median
alcohol consumption was 7.8 g/d higher in males carrying the
ADH1B*1/1 genotype as compared to males with the ADH1B*1/2
or ADH1B*2/2 genotype, respectively (Figure 1; p=0.001). The
same tendency was observed in women, but the differences in
alcohol consumption were very low (1.6 g/d; p=0.046).
In multivariable-adjusted models ADH1C and ADH1B geno-
types were not significantly associated with risk of MI or stroke in
our cohort (Figures 2A and 3A). Further adjustment for baseline
alcohol consumption only slightly changed risk estimates related to
ADH1C (Figure 2B), whereas the association between ADH1B*1/1
genotype and risk of MI became statistically significant
(HR=2.11; 95% CI: 1.02–4.05; Figure 3B). We also analyzed
the association between ADH1C and risk of CVD stratified by
alcohol consumption level (Table S1). For MI, the majority of risk
estimates were not significantly different from unity. While women
consuming .12 g/d and men consuming .24 g/d had a
decreased risk of MI in all strata of ADH1C, this finding was
statistically significant only for the ADH1C*1/2 genotype. In
comparison, individuals belonging to the highest consumption
category and carrying the slow-metabolizing ADH1C*2/2 geno-
type were found to be at an increased risk of stroke. Probability
values for interaction between ADH1C genotype and alcohol
consumption were 0.097 for MI and 0.074 for stroke. Because of
insufficient case numbers at some indicator levels, no equivalent
analyses were performed for ADH1B.
When pooling results from eligible prospective studies, the overall
RR of CVD was 1.07 (95% CI: 0.90–1.27; p for heterogeneity
0.098) for individuals carrying the ADH1C*2/2 slow metabolizing
genotype as compared to ADH1C*1/1 (Figure 2A). Subgroup
analyses did not indicate differences in risk estimates between
ischemicheartdiseaseandstroke.FourpublicationsprovidedHRof
CVD associated with ADH1C*2/2 upon adjustment for alcohol
consumption and pooling them resulted in a RR=1.05 (95% CI:
0.83–1.32). Results from Begg’s rank correlation test (p=0.484) and
Egger’s (p=0.582) indicated no significant evidence of publication
bias. The funnel plot revealed a largely symmetrical distribution
around the RR of 1, however, with a certain clustering around the
standard error of 0.2 (Figure S1). Furthermore, the two studies with
the lowest risk estimates [8,9] and one with the largest risk estimate
[7] were outside the lower 95% confidence limit. For the
comparison between ADH1B*1/1 carriers and individuals with
ADH1B*1/2 or 2/2, we were unable to obtain risk estimates of one
study. Thus, pooling our results with those of the only available




.0t o6g / d
n=137 (16.8%)
.6t o1 2g / d
n=135 (16.6%)
.12 to 24 g/d
n=200 (24.5%)




Age, y, mean 6 SD 49.768.6 52.868.3 53.067.9 51.768.2 51.468.0 53.068.1
BMI, kg/m
2, mean 6 SD 25.363.9 26.664.0 27.163.7 26.763.4 26.563.1 26.964.0
Waist circumference, cm, mean 6 SD 90.5611.5 92.969.9 94.7610.2 93.969.7 93.769.3 95.6612.1
ADH1C genotype, %
ADH1C*1/1 (fast) 34.6 32.8 39.3 35.0 34.2 31.7
ADH1C*1/2 (intermediate) 46.2 48.2 41.5 46.0 48.2 46.7
ADH1C*2/2 (slow) 19.2 19.0 19.3 19.0 17.5 21.7
ADH1B*1/1 (slow) 96.2 83.9 92.6 94.0 93.4 98.3
Smoking status, %
Never smokers 7.7 35.8 34.1 33.5 25.7 16.7
Past smokers .5 years 23.1 32.1 26.7 37.0 39.7 38.3
Past smokers #5 years 3.8 8.0 13.3 7.5 8.2 6.7
Current smokers ,20 units 26.9 12.4 17.0 16.0 16.7 20.0
Current smokers $20 units 38.5 11.7 8.9 6.0 9.7 18.3
University degree, % 38.5 46.0 57.8 52.5 61.9 41.7
Physical activity $2 h/week, % 15.4 26.3 22.2 22.0 26.8 23.3
Hypertension, % 53.8 49.6 63.0 60.5 57.2 63.3
Diabetes mellitus, % 15.4 5.8 7.4 4.5 3.5 10.0
Total cholesterol, mg/dl, mean 6 SD 171.4655.3 170.2631.4 175.8637.0 178.6633.1 179.5641.3 186.3636.7
doi:10.1371/journal.pone.0032176.t002
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1.88;p forheterogeneity0.364;Figure3A).Thisassociation became
somewhat stronger after pooling risk estimates which were
additionally adjusted for alcohol consumption (RR=1.44; 95%
CI: 0.99–2.08; Figure 3B).
Discussion
In this case-cohort study nested within the EPIC-Potsdam
cohort, risk of MI but not risk of stroke tended to decrease with
increasing alcohol consumption. Although there was a trend
towards higher alcohol consumption in individuals with the slow-
metabolizing ADH1B*1/1 variant, we found no statistically
significant relation between ADH1B or ADH1C genotypes and
risk of cardiovascular events in our data and after pooling results of
eligible prospective studies.
The J-shaped relation between alcohol consumption and risk of
CHD is well established. In a meta-analysis of 28 cohort studies,
RR of CHD gradually decreased up to a daily alcohol
consumption of 20 g and the inverse association remained
Table 3. Relative Risks of MI and stroke across categories of baseline alcohol consumption in women.
Outcome 0 g/d .0t o6g / d .6t o1 2g / d .12 to 24 g/d .24 g/d
MI
Cases (n) 5 40 12 4 0
Person-Years 285 5966 2735 1553 805
HR (95% CI)
Model 1 0.99 (0.30, 3.23) 1 (Ref) 0.74 (0.36, 1.53) 0.31 (0.10, 0.97) n.a.
Model 2 0.72 (0.19, 2.81) 1 (Ref) 0.75 (0.36, 1.55) 0.30 (0.10, 0.91) n.a.
Model 3 1.14 (0.35, 3.73) 1 (Ref) 0.69 (0.32, 1.48) 0.32 (0.10, 1.03) n.a.
Stroke
Cases (n) 6 47 23 12 7
Person-Years 295 5983 2757 1582 835
HR (95% CI)
Model 1 1.70 (0.66, 4.40) 1 (Ref) 1.26 (0.73, 2.17) 1.00 (0.51, 1.98) 1.05 (0.43, 2.58)
Model 2 1.32 (0.46, 3.81) 1 (Ref) 1.27 (0.73, 2.22) 0.98 (0.50, 1.92) 0.87 (0.35, 2.19)
Model 3 1.71 (0.67, 4.38) 1 (Ref) 1.24 (0.71, 2.13) 1.00 (0.50, 1.99) 1.03 (0.41, 2.56)
Model 1 stratified by age at recruitment and adjusted for BMI, waist circumference, smoking status, educational attainment, physical activity, non-alcohol energy intake,
prevalent hypertension, prevalent diabetes mellitus, and plasma total cholesterol level.
Model 2: Model 1 plus past alcohol consumption.
Model 3: Model 1 plus ADH1C and ADH1B genotypes.
doi:10.1371/journal.pone.0032176.t003
Table 4. Relative Risks of MI and stroke across categories of baseline alcohol consumption in men.
Outcome 0 g/d .0t o6g / d .6t o1 2g / d .12 to 24 g/d .24 to 60 g/d .60 g/d
MI
Cases (n) 11 39 35 32 45 7
Person-Years 226 1231 1247 1755 2227 508
HR (95% CI)
Model 1 1.48 (0.61, 3.58) 1 (Ref) 0.76 (0.44, 1.33) 0.56 (0.32, 1.00) 0.57 (0.33, 0.98) 0.30 (0.12, 0.78)
Model 2 1.38 (0.54, 3.55) 1 (Ref) 0.76 (0.44, 1.33) 0.57 (0.32, 1.00) 0.56 (0.32, 0.97) 0.27 (0.10, 0.74)
Model 3 1.37 (0.57, 3.28) 1 (Ref) 0.69 (0.39, 1.22) 0.51 (0.29, 0.91) 0.53 (0.31, 0.90) 0.27 (0.10, 0.71)
Stroke
Cases (n) 6 18 18 24 36 11
Person-Years 215 1144 1174 1747 2185 520
HR (95% CI)
Model 1 3.57 (1.13, 11.32) 1 (Ref) 0.98 (0.47, 2.02) 1.13 (0.57, 2.24) 1.57 (0.82, 3.00) 1.50 (0.67, 3.36)
Model 2 3.69 (1.07, 12.69) 1 (Ref) 0.98 (0.47, 2.03) 1.13 (0.57, 2.24) 1.59 (0.83, 3.04) 1.53 (0.67, 3.50)
Model 3 3.48 (1.10, 10.95) 1 (Ref) 0.94 (0.45, 1.94) 1.11 (0.56, 2.20) 1.54 (0.80, 2.95) 1.46 (0.65, 3.28)
Model 1 stratified by age at recruitment and adjusted for BMI, waist circumference, smoking status, educational attainment, physical activity, non-alcohol energy intake,
prevalent hypertension, prevalent diabetes mellitus, and plasma total cholesterol level.
Model 2: Model 1 plus past alcohol consumption.
Model 3: Model 1 plus ADH1C and ADH1B genotypes.
doi:10.1371/journal.pone.0032176.t004
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above mentioned findings, we observed a decreased risk of MI for
women consuming .12 g alcohol/d and men consuming .24 g/
d. Yet we had limited ability to examine MI risk associated with
excessive drinking. Our finding of a ,70% decreased risk of MI in
men consuming .60 g/d was based on only seven cases and
should be interpreted with caution. In women, the case numbers
were quite low in any but the reference category and no female
participant consuming .24 g alcohol/d suffered a MI during
follow-up.
In contrast to our findings on MI, risk of stroke was not
significantly related to alcohol consumption above 6 g/d. A J-
shaped association between alcohol consumption and risk of stroke
– most notably ischemic stroke – has been confirmed by several
meta-analyses [1,34,35]. However, compared to CHD, the
reduction in stroke risk is less pronounced and limited to lower
consumption levels [1,34]. Accordingly, our reference group is
composed of individuals at low risk of stroke and therefore it is not
surprising that we did not observe statistically significant risk
estimates below unity. In men but not in women we also observed
an increase in risk of stroke for individuals with higher alcohol
consumption. Although not statistically significant, this data is in
line with epidemiological evidence [1,34,35].
We were unable to provide risk estimates for lifelong abstainers
from alcohol as only one man and 14 women of the analytical
study population fell in this category. Therefore, the risk of CVD
associated with zero alcohol consumption mainly reflects the
group of study participants who had consumed alcohol in their
past. This group may contain individuals who became abstainers
from alcohol because of illness, illness-related need for medication
or as they age. We tried to acknowledge this point by adjusting for
prevalent diseases and by using individuals with very low alcohol
consumption (.0 to 6 g/d) rather than abstainers as the reference
group. The latter is justified by meta-analyses showing that former
drinking is associated with an increased risk of CHD- and CVD-
mortality [1,36]. Whilst alcohol consumption of 0 g/d was not
significantly related to risk of MI in our data, we observed a
threefold increased risk of stroke in male abstainers from alcohol
(HR=3.57; 95% CI: 1.13–11.32). This finding even persisted after
additional adjustment for lifetime alcohol consumption suggesting
that changes in drinking behavior or periods of heavy drinking in
the past are not the major reason why male abstainers of alcohol
were at an increased stroke risk. However, risk estimates for this
group were highly imprecise, as reflected by the broad 95% CI.
Therefore, it is difficult to judge the strength of the association.
Potential protective effects of moderate alcohol drinking and rise
in CVD risk associated with non-drinking have received a lot of
attention. Although the impact of ethanol on lipoproteins, insulin
sensitivity, and haemostasis provides biologically plausible path-
ways [2,37], observational studies are limited in their ability to
prove causality. In this respect, genetic variants associated with
median alcohol consumption and/or circulating ethanol levels
may act as unconfounded and precisely measured markers of the
exposure and thereby contributing to strengthen causal inference
[3]. In our study, a polymorphism in ADH1B was associated with
average alcohol consumption. As expected from the higher
tolerance to ethanol, individuals with the respective slow
metabolizing genotype tended to consume higher amounts of
alcohol than those carrying the genotype coding for the more
active isoenzyme. These findings are in line with recent data
showing that carriers of the rs1229984 G-allele (ADH1B*1)
differed from those with the A-allele by a higher overall alcohol
consumption. In this study, individuals with the G-allele even
reported a higher number of drinking occasions and a higher
maximum number of alcoholic drinks in a single day. Though to a
lesser extent, the same tendency has been observed for rs1693482
Figure 1. Median baseline alcohol consumption across genotypes of ADH1C and ADH1B. Data derived from 815 men and 1360 women of a
randomly drawn subcohort of the EPIC-Potsdam study.
doi:10.1371/journal.pone.0032176.g001
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32176Figure 2. Relative Risks and 95% CI from a meta-analysis of rs698 or rs1693482 in the ADH1C gene and CVD. Estimates are for the
comparison of the slow-coding genotype (ADH1C*2/2) with the fast-coding genotype (ADH1C*1/1) (A) Including risk estimates not adjusted for
alcohol consumption. (B) Including risk estimates adjusted for alcohol consumption. Data for the Second Northwick Park Heart Study obtained by
personal communication with the corresponding author.
doi:10.1371/journal.pone.0032176.g002
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disequilibrium with the one used in our study (rs698), we did not
observe diversity in alcohol consumption across ADH1C geno-
types. However, kinetic differences between ADH1C-isoenzymes
are much less pronounced than those between ADH1B-isoen-
zymes [4] and therefore the impact on alcohol consumption may
have been too small to be detectable with our dietary assessment
instrument.
If a slower rate of ethanol clearance enhances the beneficial
effect of moderate alcohol consumption on the risk of CVD,
polymorphisms in ADH coding for slow ethanol metabolism
should be associated with a decreased risk of CVD. Indeed, Hines
et al. observed a decreased risk of MI in individuals with the
ADH1C*2/2 polymorphism as compared to ADH1C*1/1 [9]. Yet,
we found no such evidence in our data and after pooling the RRs
of eligible prospective studies [stroke: RR=1.15 (95% CI 0.85–
1.55); ischemic heart disease: RR=1.04 (95% CI 0.84–1.29)].
Consistent with the overall null-finding observed in prospective
studies, prevalence of CVD did not differ significantly by SNPs of
the ADH1C gene (rs1693482 and rs698) in a cross-sectional
analysis of the Framingham Offspring Study [5].
To our knowledge, our study is the first investigating the
association between ADH1B genotype and risk of stroke
prospectively. Contrary to our hypothesis, we found a tendency
towards an increased risk of coronary and cerebral events in
carriers of the ADH1B*1/1 slow metabolizing genotype. However,
only one Danish population [10] and our cohort contributed to
these findings. ADH1B genotypes have also been assessed in a case-
Figure 3. Relative Risks and 95% CI of CVD from a meta-analysis of rs1229984 in the ADH1B gene and CVD. Estimates are for the
comparison of the slow-coding genotype (ADH1B*1/1) with the fast-coding genotype (ADH1B*1/2 or 2/2). (A) Including risk estimates not adjusted for
alcohol consumption. (B) Including risk estimates adjusted for alcohol consumption.
doi:10.1371/journal.pone.0032176.g003
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and Health Study, for which we were unable to obtain risk
estimates [11]. However, the raw frequencies of ADH1B genotypes
in cases and the random subcohort are nearly identical. Although
standard methods for calculating RR and the standard error based
on raw data are not applicable for the case-cohort design, the
respective RR of acute coronary syndrome is likely to be close to 1.
This data further supports the overall null-finding of our meta-
analysis.
One may speculate that any potentially protective effect of slow
ethanol oxidation might be counterbalanced by a higher tolerance
to ethanol and thus a higher probability for hazardous alcohol
consumption. However, adjustment for alcohol consumption did
not materially change pooled risk estimates for ADH1C*2/2,
whereas the association between ADH1B*1/1 and risk of CVD
was even strengthened. Additionally, the impact of genotypes in
ADH may only be observable in individuals with a given level of
regular alcohol consumption. For the meta-analysis, we did not
attempt to pool risk estimates of ADH genotypes by strata of
alcohol consumption because of rather heterogeneous consump-
tion categories - especially with regards to the reference category.
Yet, previous studies analyzing this issue were rather inconsistent
showing the strongest inverse association between ADH1C*2/2
genotype and risk of coronary events either in men with the
highest alcohol consumption of at least one drink/d [8,9], or in
men with a modest consumption of 1–3 alcoholic beverages/week
[12]. Other studies provided little evidence for an association
between ADH1C genotype and coronary events [10,11] or stroke
[13] across strata of alcohol consumption and the same applies to
the association between ADH1B genotype and acute coronary
syndrome [11]. In our study, there was no clear evidence that the
slow-metabolizing ADH1C*2/2 genotype decreases risk of CVD in
any stratum of alcohol consumption (Table S1). Rather, we
observed an increased risk of stroke in study participants with this
genotype who exceeded the recommended upper limit of alcohol
consumption of two standard drinks a day for men (24 g/d) and
one standard drink a day for women (12 g/d) [24]. Although a
chance finding cannot be ruled out, a slow conversion of ethanol
to acetaldehyde may also amplify the well-established rise in stroke
risk associated with higher consumption levels. Among abstainers
from alcohol, only 16 cases of MI and 12 cases of stroke have been
observed (including 1 and 3 lifelong abstainers, respectively). That
is why risk estimates were highly imprecise for this group, but a
tendency towards an increased risk of CVD was apparent in most
strata of the ADH1C genotype. Therefore, the potential of
negatively biasing the reference group by including former
drinkers should also be acknowledged in studies investigating
interactions between genetic variants with alcohol consumption.
Taken together, we observed the expected association between
alcohol consumption and risk of MI or stroke, respectively. Yet,
genetic variants in ADH1B and ADH1C had a minor influence on
the above associations and were not significantly related to the
incidence of cardiovascular events. Because of this discrepancy in
findings, one may speculate that residual confounding, misreport-
ing of alcohol consumption or constituents of alcoholic beverages
other than ethanol are responsible for the well-documented J-
shaped association between alcohol consumption and cardiovas-
cular events. Given the consistency of epidemiological data across
several populations with different drinking behaviors, these effects
would need to be strong. Alternatively, the in vivo effect of the
investigated genetic variants on circulating ethanol levels or
alcohol drinking behaviors may not be sufficient to make causal
inference about the role of alcohol consumption on the
investigated outcomes. For a Mendelian Randomization ap-
proach, genetic variants of ALDH2 with a strong influence on
alcohol consumption might be more promising and have been
successfully applied to study the impact of alcohol consumption on
hypertension [39] and esophageal cancer [40]. On the other hand,
the principal applicability of ADH gene variants has been
demonstrated by recent studies showing that a slow-metabolizing
genotype increases the risk of cancers of the upper aerodigestive
tract [41,42]. However, a large fraction of these cancers is believed
to be attributable to alcohol consumption [43], making them a
promising target to investigate genetically determined differences
in ethanol metabolism. In comparison, the association between
alcohol consumption and risk of CVD is less strong and not even
linear. Thus, we can not exclude a causal effect of alcohol
consumption on CVD risk, but the investigated genetic polymor-
phisms in ADH1B and ADH1C do not mirror such an effect.
Our study benefits from a well-characterized study population
embedded into the EPIC-Potsdam cohort with detailed assessment
of baseline and past alcohol consumption. Data were collected
prospectively and follow-up proportions exceeded 90% [19]. As
we used a case-cohort design, our findings are expected to be
generalizable to the source population without the need to assess
genotypes in the entire cohort [18]. Compared to data obtained by
multiple 24-hour diet recalls, the validity of self-reported alcohol
consumption in the FFQ was very good [44]. We confined our
meta-analysis to prospective studies to reduce the possibility that
genotypes potentially associated with the severity of disease may
affect the participation rate. As only two study populations on
ADH1B polymorphisms met our inclusion criteria, we still had
limited power to detect changes in CVD risk associated with the
slow-metabolizing ADH1B*1/1 genotype. Despite this limitation
we believe that low statistical power can not completely explain
our findings because pooled risk estimates are not in the expected
direction. In addition, cross-sectional or retrospective data on this
topic are also inconsistent. In a hospital-based case-control study
from China, a somewhat lower prevalence of the slow-coding
ADH1B*1/1 genotype was observed in patients with premature
coronary artery disease (CAD) as compared to patients with late
onset CAD (6.6% vs. 12.3%; p=0.064) [45]. In comparison, male
but not female carriers of the ADH1B*1 allele had a higher
prevalence of cerebral and lacunal infarction in a cross-sectional
Japanese study [15].
In summary, we found increasing alcohol consumption to be
associated with a decreased risk of MI, whereas there was a
tendency towards an increased risk of stroke. Contrary to our
hypothesis, however, polymorphisms in ADH1B and ADH1C with
an influence on the rate of ethanol oxidation do neither explain
nor reflect the well-described impact of alcohol consumption on
CVD risk.
Supporting Information
Figure S1 Funnel Plot for association studies of rs698 or
rs1693482 in the ADH1C gene and CVD. Solid vertical line
represents summary risk estimate from random effects meta-
analysis. Dashed lines represent 95% CI for the expected
distribution of studies in absence of heterogeneity. [1] Data from
the EPIC-Potsdam study [12]. Unpublished data from the Second
Northwick Park Heart Study, obtained by personal communica-
tion with the corresponding author.
(TIF)
Table S1 Relative Risks of MI and stroke across
genotypes of ADH1C and categories of baseline alcohol
consumption. Footnote:
1Stratified by age at recruitment and
adjusted for gender, BMI, waist circumference, smoking status,
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intake, prevalent hypertension, prevalent diabetes mellitus, and
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